NovoCure (NVCR) Total Non-Current Liabilities (2014 - 2026)

NovoCure (NVCR) has reported Total Non-Current Liabilities for 13 consecutive years, with $236.4 million the latest figure, recorded in Q2 2026.

• Quarterly Total Non-Current Liabilities rose 61.03% year-over-year to $236.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $236.4 million (up 61.03% YoY) and the FY2025 annual result came in at $240.6 million, up 93.73% from the prior year.
• Total Non-Current Liabilities eased to $236.4 million in Q2 2026 per NVCR's latest filing, from $239.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for NVCR reached as high as $681.2 million in Q2 2024 and fell as low as $124.2 million in Q4 2024.
• A 5-year average of $417.9 million and a median of $586.1 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 79.45% — and 2025, when it soared 93.73%.
• Year by year, Total Non-Current Liabilities stood at $591.7 million in 2022, then increased by 2.17% to $604.5 million in 2023, then tumbled by 79.45% to $124.2 million in 2024, then jumped by 93.73% to $240.6 million in 2025, then declined by 1.76% to $236.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $236.4 million, $239.6 million, and $240.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.